Essential Premium Newsletter Institutional Investor stories focused on hedge funds and alternatives. December 31, 2023 This email is sent out twice a week and covers hedge fund related topics.View a sample Related Articles Biopharma Hedge Funds Diverge in March as Avoro Surges Stephen Taub Investor Advocates Ask FASB to Reconsider Guidance on Secondaries Michelle Celarier From Informing AI to Empowering Traders, Quality Data is Non-Negotiable Sponsored by CME Group